Details

Autor(en) / Beteiligte

• Masana, Luis
• Díaz Moya, Gema
• Pérez de Isla, Leopoldo
• Plana, Núria
• Andreychuk, Natalia
• Ruiz Ortiz, Martín
• Herrera, Norberto
• José Gómez Doblas, Juan
• Rodríguez Capitán, Jorge
• Vazquez Garcia, Rafael
• Bartolomé, Daniel
• Delgado, William
• Caldés, Onofre
• Gil, Aritz
• Perea, Verònica
• Sionis, Alessandro
• Herráez, Silvia
• Jericó, Carles
• Pintó, Xavier
• María de los Ángeles Rodríguez
• Domènech, Mònica
• Luis Santos, José
• Enriquez, Eduardo
• Arribas, Patricio
• García Corrales, Carmen
• Bravo Amaro, Marisol
• González, Inmaculada
• Caneiro, Berenice
• Gonzalez Juanatey, Carlos
• Méndez Eirin, Elizabet
• Curcio Ruigómez, Alejandro
• María Jiménez, Rosa
• Cristobal, Carmen
• Armada Romero, Eduardo
• Briongos, Sem
• Gabriela Vallarino Terán, Varinia
• Pascual, Domingo
• Marín Ortuño, Francisco
• Tello Montoliu, Antonio
• Roy, Ignacio
• Facila Rubio, Lorenzo
• Montagud, Vicente
• Bonanat, Clara
• Arrarte Esteban, Vicente
• Fuertes, Laura
• María García, Ana
• Cordero, Alberto
• Ángel Arnau, Miguel
• Domingo Valero, Diana

Titel

Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets

Ist Teil von

• Nutrition, metabolism, and cardiovascular diseases, 2024-01, Vol.34 (1), p.90-97

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Despite considerable evidence that lipid-lowering therapies (LLTs) afford clinical benefit, the control of low-density lipoprotein cholesterol (LDL-C) is suboptimal, and available LLTs are underused, especially in patients at high and very high cardiovascular (CV) risk. This study assesses the real-world LDL-C target attainment rate in patients on LLT before experiencing a first major acute cardiovascular event (MACE). The HEARTBEAT was a retrospective, multicentre observational study. From March to June 2021 a total of 334 patients on LLT who had a first MACE while being on statins were included in the study. Of these patients, 83.2 % had a high (40.7 %) or very high CV risk (29.0 %) prior to MACE. Overall, 87.5 % and 89.7 % of the patients at high and very high CV risk, respectively, failed to reach the LDL-C target. Regarding LLTs, only 11.8 % and 19.6 % of the patients at high and very high risk had received high-intensity LLTs prior to MACE. It was estimated that if these patients had reached their recommended LDL-C targets, the risk of MACE may have been reduced by a median of 24.5 % and 23.2 % in patients at high and very high risk respectively. Patients who suffer a first MACE while on statin therapy often were at high/very high CV risk. Despite their risk, LDL-levels and being on statins they are undertreated, and too far from lipid targets. A proper use of high-intensity LLTs led to an increase attainment of LDL targets and lower CV events. [Display omitted] •Patients taking statins for primary prevention in Spain are too far of lipid target.•This occurs especially in those at high and very high cardiovascular (CV) risk.•High-intensity lipid-lowering therapies (LLTs) are underused in primary prevention.•A proper use of LLTs would increase the number of patients achieving LDL-C targets.•Moreover, the number of CV events would be significantly reduced.